TY - JOUR
T1 - Genetic and Clinical Predictors of Age of ESKD in Individuals With Autosomal Dominant Tubulointerstitial Kidney Disease Due to UMOD Mutations
AU - Kidd, Kendrah
AU - Vylet'al, Petr
AU - Schaeffer, Céline
AU - Olinger, Eric
AU - Živná, Martina
AU - Hodaňová, Kateřina
AU - Robins, Victoria
AU - Johnson, Emily
AU - Taylor, Abbigail
AU - Martin, Lauren
AU - Izzi, Claudia
AU - Jorge, Sofia C.
AU - Calado, Joaquim
AU - Torres, Rosa J.
AU - Lhotta, Karl
AU - Steubl, Dominik
AU - Gale, Daniel P.
AU - Gast, Christine
AU - Gombos, Eva
AU - Ainsworth, Hannah C.
AU - Chen, Ying Maggie
AU - Almeida, Jorge Reis
AU - de Souza, Cintia Fernandes
AU - Silveira, Catarina
AU - Raposeiro, Rita
AU - Weller, Nelson
AU - Conlon, Peter J.
AU - Murray, Susan L.
AU - Benson, Katherine A.
AU - Cavalleri, Gianpiero L.
AU - Votruba, Miroslav
AU - Vrbacká, Alena
AU - Amoroso, Antonio
AU - Gianchino, Daniela
AU - Caridi, Gianluca
AU - Ghiggeri, Gian Marco
AU - Divers, Jasmin
AU - Scolari, Francesco
AU - Devuyst, Olivier
AU - Rampoldi, Luca
AU - Kmoch, Stanislav
AU - Bleyer, Anthony J.
N1 - Funding Information:
This study was funded by National Institutes of Health (NIH)– National Institute of Diabetes and Digestive and Kidney Diseases R21 DK106584 . Wake Forest also thanks the Black-Brogan Foundation for support. YMC was supported by NIH grants R01 DK105056A1 , R03DK106451 , and K08DK089015 ; The Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense , Award Number W81XWH-19–1–0320 . PV, MŽ, and SK were supported by grant NV17–29786A from the Ministry of Health of the Czech Republic and by institutional programs of Charles University in Prague (UNCE/MED/007 and PROGRES-Q26/LF1); they thank The National Center for Medical Genomics ( LM2015091 ) for help in genotyping. EO is supported by the Fonds National de la Recherche Luxembourg ( 6903109 ). OD is supported by the European Reference Network for Rare Kidney Diseases (ERKNet), project ID No. 739532; the National Centre for Competence in Research Kidney CH program; and the Swiss National Science Foundation 310030–189044 . LR was supported by the Italian Society of Nephrology (SIN) under the “Adotta un progetto di ricerca” program, Telethon-Italy (GGP14263); the Ministry of Health of Italy (grant RF-2010–2319394 and RF-2016–02362623 ), Soli Deo Gloria.
Funding Information:
We thank all participating patients and families, and the referring physicians. We acknowledge Sebastiano Regina (San Luigi Gonzaga University Hospital) and Alessandra Cuccurullo (University of Turin) for genotyping, Alessandra Pelle (University of Turin) for genetic counseling, and Elena Pasqualetto (San Raffaele Scientific Institute) for in vitro studies. This study was funded by National Institutes of Health (NIH)?National Institute of Diabetes and Digestive and Kidney Diseases R21 DK106584. Wake Forest also thanks the Black-Brogan Foundation for support. YMC was supported by NIH grants R01 DK105056A1, R03DK106451, and K08DK089015; The Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, Award Number W81XWH-19?1?0320. PV, M?, and SK were supported by grant NV17?29786A from the Ministry of Health of the Czech Republic and by institutional programs of Charles University in Prague (UNCE/MED/007 and PROGRES-Q26/LF1); they thank The National Center for Medical Genomics (LM2015091) for help in genotyping. EO is supported by the Fonds National de la Recherche Luxembourg (6903109). OD is supported by the European Reference Network for Rare Kidney Diseases (ERKNet), project ID No. 739532; the National Centre for Competence in Research Kidney CH program; and the Swiss National Science Foundation 310030?189044. LR was supported by the Italian Society of Nephrology (SIN) under the ?Adotta un progetto di ricerca? program, Telethon-Italy (GGP14263); the Ministry of Health of Italy (grant RF-2010?2319394 and RF-2016?02362623), Soli Deo Gloria.
Publisher Copyright:
© 2020 International Society of Nephrology
PY - 2020/9
Y1 - 2020/9
N2 - Introduction: Autosomal dominant tubulo-interstitial kidney disease due to UMOD mutations (ADTKD-UMOD) is a rare condition associated with high variability in the age of end-stage kidney disease (ESKD). The minor allele of rs4293393, located in the promoter of the UMOD gene, is present in 19% of the population and downregulates uromodulin production by approximately 50% and might affect the age of ESKD. The goal of this study was to better understand the genetic and clinical characteristics of ADTKD-UMOD and to perform a Mendelian randomization study to determine if the minor allele of rs4293393 was associated with better kidney survival. Methods: An international group of collaborators collected clinical and genetic data on 722 affected individuals from 249 families with 125 mutations, including 28 new mutations. The median age of ESKD was 47 years. Men were at a much higher risk of progression to ESKD (hazard ratio 1.78, P < 0.001). Results: The allele frequency of the minor rs4293393 allele was only 11.6% versus the 19% expected (P < 0.01), resulting in Hardy-Weinberg disequilibrium and precluding a Mendelian randomization experiment. An in vitro score reflecting the severity of the trafficking defect of uromodulin mutants was found to be a promising predictor of the age of ESKD. Conclusion: We report the clinical characteristics associated with 125 UMOD mutations. Male gender and a new in vitro score predict age of ESKD.
AB - Introduction: Autosomal dominant tubulo-interstitial kidney disease due to UMOD mutations (ADTKD-UMOD) is a rare condition associated with high variability in the age of end-stage kidney disease (ESKD). The minor allele of rs4293393, located in the promoter of the UMOD gene, is present in 19% of the population and downregulates uromodulin production by approximately 50% and might affect the age of ESKD. The goal of this study was to better understand the genetic and clinical characteristics of ADTKD-UMOD and to perform a Mendelian randomization study to determine if the minor allele of rs4293393 was associated with better kidney survival. Methods: An international group of collaborators collected clinical and genetic data on 722 affected individuals from 249 families with 125 mutations, including 28 new mutations. The median age of ESKD was 47 years. Men were at a much higher risk of progression to ESKD (hazard ratio 1.78, P < 0.001). Results: The allele frequency of the minor rs4293393 allele was only 11.6% versus the 19% expected (P < 0.01), resulting in Hardy-Weinberg disequilibrium and precluding a Mendelian randomization experiment. An in vitro score reflecting the severity of the trafficking defect of uromodulin mutants was found to be a promising predictor of the age of ESKD. Conclusion: We report the clinical characteristics associated with 125 UMOD mutations. Male gender and a new in vitro score predict age of ESKD.
KW - autosomal dominant uromodulin kidney disease
KW - genotype
KW - phenotype
KW - rs4293393
KW - uromodulin
UR - http://www.scopus.com/inward/record.url?scp=85089590074&partnerID=8YFLogxK
U2 - 10.1016/j.ekir.2020.06.029
DO - 10.1016/j.ekir.2020.06.029
M3 - Article
C2 - 32954071
AN - SCOPUS:85089590074
SN - 2468-0249
VL - 5
SP - 1472
EP - 1485
JO - Kidney International Reports
JF - Kidney International Reports
IS - 9
ER -